bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
P/E ratio for bluebird bio, Inc. (BLUE)
P/E ratio as of 2023: -0.72
According to bluebird bio, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.72. At the end of 2022 the company had a P/E ratio of -2.04.
P/E ratio history for bluebird bio, Inc. from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.72 |
| 2022 | -2.04 |
| 2021 | -1.22 |
| 2020 | -2.82 |
| 2019 | -3.97 |
| 2018 | -6.02 |
| 2017 | -14.96 |
| 2016 | -5.65 |
| 2015 | -8.65 |
| 2014 | -32.37 |
| 2013 | -6.74 |
| 2012 | -16.80 |
| 2011 | -25.49 |